electroCore (NASDAQ:ECOR) Stock Price Expected to Rise, HC Wainwright Analyst Says

electroCore (NASDAQ:ECOR) had its target price boosted by stock analysts at HC Wainwright from $22.00 to $25.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 79.47% from the stock’s previous close.

electroCore Stock Performance

Shares of ECOR opened at $13.93 on Wednesday. The company has a 50-day simple moving average of $11.22 and a 200-day simple moving average of $8.02. The firm has a market capitalization of $91.31 million, a P/E ratio of -7.61 and a beta of 0.57. electroCore has a 52 week low of $5.21 and a 52 week high of $15.25.

Institutional Investors Weigh In On electroCore

A number of institutional investors have recently bought and sold shares of ECOR. International Assets Investment Management LLC raised its holdings in shares of electroCore by 689.1% in the 3rd quarter. International Assets Investment Management LLC now owns 535,146 shares of the company’s stock worth $3,864,000 after buying an additional 467,326 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of electroCore by 3.4% during the second quarter. Renaissance Technologies LLC now owns 68,786 shares of the company’s stock valued at $442,000 after acquiring an additional 2,270 shares during the period. Geode Capital Management LLC raised its holdings in electroCore by 10.3% during the 3rd quarter. Geode Capital Management LLC now owns 63,485 shares of the company’s stock worth $458,000 after purchasing an additional 5,951 shares during the last quarter. Finally, HighTower Advisors LLC bought a new stake in shares of electroCore during the third quarter worth approximately $255,000. Institutional investors and hedge funds own 26.74% of the company’s stock.

About electroCore

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.